Determination of Bioequivalence of Cefixime by Three-way Crossover Design

OBJECTIVE:To study the bioequivalence of suspension formulation of cefixime(A),capsule formulation of ce-fixime(B) and reference preparation(C: Cefixime Capsules or Cefspan) in human body.METHODS: The study was conducted as a 3- way crossover design in 18 healthy volunteers whose plasma concentrations of cefixime were determined by HPLC after receiving a single oral dose of 200 mg trial preparations or reference preparation.RESULTS:The main pharmacokinetics of the three preparations(A、B、C) were as follows after undergoing BIO3 program fitting:AUC0-1 were(18.54±6.31)mg·h-1·L-1, (16.10±5.51)mg·h-1·L-1 and (17.16±5.96)mg·h-1·L-1, Cmax were(2.63±0.76) mg·L-1, (2.43±0.78)mg·L-1 and (2.57±0.90)mg·L-1;tmax were(4.11±0.58)h,(4.56±0.51)h and (4.56±0.70)h,respectively .The relative bioavailability of cefixime suspensions(A) and cefixime capsules(B) were (108.8±12.3)% and (95.7±15.9)% ,respectively as against reference preparation(C) .CONCLUSION:The test formulations(A and B) were found bioequivalent to the reference formulation(C).